Daily Anesthesiology Research Analysis
Analyzed 107 papers and selected 3 impactful papers.
Summary
A network meta-analysis of 32 randomized trials in elderly spinal surgery patients identifies dexmedetomidine as the most reliable prevention strategy for postoperative delirium, with temperature protection plus dexmedetomidine, melatonin, and goal-directed fluid therapy also ranking highly. A randomized trial shows that administering propofol before remifentanil reduces hypoxemia during gastroscopy in obese patients. A large population-based model (HOMEDAYS) accurately predicts days at home within 90 days after gastrointestinal cancer surgery, enabling patient-centered perioperative counseling.
Research Themes
- Delirium prevention strategies in perioperative care
- Respiratory safety optimization during procedural sedation
- Patient-centered outcomes prediction and perioperative risk communication
Selected Articles
1. Efficacy of preventive interventions for postoperative delirium in elderly patients undergoing spinal surgery: A network meta-analysis of randomized controlled trials.
This network meta-analysis of 32 RCTs (n=3,454) in elderly spinal surgery ranked dexmedetomidine as the most reliable prevention for postoperative delirium, with temperature protection plus dexmedetomidine, melatonin, and goal-directed fluid therapy also highly ranked. Only dexmedetomidine had moderate-certainty evidence; other promising strategies require confirmation and international validation.
Impact: Provides comparative effectiveness ranking across multiple prophylactic strategies for postoperative delirium, prioritizing dexmedetomidine with moderate-certainty evidence and informing perioperative protocols.
Clinical Implications: Dexmedetomidine should be considered the core prophylaxis for postoperative delirium in elderly spinal surgery, while temperature management, melatonin, and goal-directed fluid therapy can be adjuncts where feasible, pending external validation.
Key Findings
- Included 32 RCTs (n=3,454) evaluating 19 interventions; network consistency supported (P=0.44).
- Top-ranked interventions by SUCRA: temperature protection+dexmedetomidine (OR 0.11), melatonin (OR 0.20), goal-directed fluid therapy (OR 0.25).
- Dexmedetomidine monotherapy is supported by moderate-certainty evidence (OR 0.35) and should be the core strategy.
- All trials conducted in China; generalizability is limited and requires international validation.
Methodological Strengths
- Frequentist random-effects network meta-analysis with low global inconsistency.
- Risk of bias assessed via Cochrane RoB 2.0; majority of trials low risk or some concerns.
- Prospective registration (PROSPERO CRD420251014832).
Limitations
- All included trials were conducted in China, limiting external validity.
- Several high-ranking nodes were informed by single or few small RCTs, lowering certainty.
- Heterogeneity in intervention dosing and perioperative protocols across trials.
Future Directions: Conduct large, multicenter, international RCTs to validate top-ranked strategies and standardize dosing/timing; evaluate combined bundles (e.g., dexmedetomidine plus temperature management) with core outcome sets for delirium.
OBJECTIVE: To compare and rank preventive interventions for postoperative delirium (POD) in elderly spinal surgery patients via network meta-analysis. METHODS: We searched major databases (inception to March 2025) for relevant randomized controlled trials (RCTs). Methodological quality was assessed using the Cochrane RoB 2.0 tool. A frequentist random-effects network meta-analysis was performed. RESULTS: Thirty-two RCTs (enrolling 3454 patients) evaluating 19 interventions were included. Most studies (n = 25) demonstrated low risk of bias or raised only some concerns. Global inconsistency assessment indicated consistency (P = 0.44). Ten interventions significantly reduced POD incidence compared to control. Surface under the cumulative ranking curve (SUCRA) analysis ranked temperature protection combined with dexmedetomidine (OR = 0.11, 95% CI: 0.02-0.59, SUCRA = 81.7%) as the most effective intervention, followed by melatonin (OR = 0.20, 95% CI: 0.05-0.81, SUCRA = 70.3%) and goal-directed fluid therapy (OR = 0.25, 95% CI: 0.09-0.66, SUCRA = 63.6%). CONCLUSIONS: Dexmedetomidine monotherapy is the only intervention supported by moderate-certainty evidence (OR = 0.35) and should be the core POD prevention strategy. Other top-ranked interventions (temperature protection+DEX, melatonin, GDFT) showed promise but are based on low-certainty evidence, often from single trials, and require confirmation. All 32 trials were from China, limiting generalizability; international validation is needed. REGISTRATION: PROSPERO CRD420251014832.
2. Comparison of the Effect of Different Administration Sequence of Propofol and Remifentanil on Sedation/Anesthesia During Gastroscopy in Obese Patients.
In a single-center RCT of 284 obese patients undergoing gastroscopy, administering propofol before remifentanil reduced hypoxemia (15.5% vs 29.6%; RR 1.44 for R-P vs P-R; P=0.007) and improved the lowest SpO2. This simple sequencing change enhances respiratory safety during procedural sedation in a high-risk population.
Impact: Demonstrates a pragmatic, easily adoptable dosing sequence to reduce hypoxemia in obese patients during endoscopy—an immediate, high-yield safety optimization for anesthesiology practice.
Clinical Implications: Adopt a propofol-first, remifentanil-second sequence for obese patients undergoing gastroscopy to reduce hypoxemia; integrate into sedation protocols and monitor SpO2 trends to confirm benefit.
Key Findings
- Randomized 296 obese patients; 284 analyzed (142 per arm) for gastroscopy sedation.
- Hypoxemia incidence reduced with propofol→remifentanil sequence: 15.5% vs 29.6% (RR 1.44 for R-P vs P-R; P=0.007).
- Lowest SpO2 improved with the propofol-first sequence (qualitatively reported in trial abstract).
Methodological Strengths
- Prospective randomized controlled design targeting a high-risk obese cohort.
- Clinically meaningful primary endpoint (hypoxemia) with clear between-group difference.
Limitations
- Single-center study limits generalizability; blinding procedures not described.
- Incomplete reporting of several secondary outcomes (e.g., exact lowest SpO2 values) in the abstract.
Future Directions: Validate findings in multicenter settings, explore optimal dosing and timing for sequence effects, and assess applicability across other endoscopic and procedural sedation contexts.
PURPOSE: Obesity is associated with an elevated risk of hypoxemia during endoscopic procedures performed under anesthesia. However, whether the sequence of drug administration - specifically the order of propofol and remifentanil - affects the incidence of hypoxemia remains unclear. This study was designed to evaluate whether a novel administration sequence, in which propofol precedes remifentanil, can decrease the incidence of hypoxemia in obese individuals during endoscopy. PATIENTS AND METHODS: This prospective, single center, randomized controlled clinical trial recruited 296 obese patients scheduled for sedative/anesthesia gastroscopy prior to bariatric surgery. Patients were randomly assigned to either novel administration sequence with propofol-remifentanil (P-R) group or conventional administration of remifentanil-propofol (R-P) group. The primary outcome was the incidence of hypoxemia. Secondary outcomes included the lowest peripheral oxygen saturation (L-SpO RESULTS: 284 patients were included in the analysis with 142 in each group. Hypoxemia occurred in 22 patients (15.5%) in the P-R group, and 42 patients (29.6%) in the R-P group (Relative Risk [RR], 1.44; 95% confidence interval [CI], 1.13 to 1.79; P = 0.007). The L-SpO CONCLUSION: Propofol first and followed by remifentanil administration sequence significantly decreased the incidence of hypoxemia and increased the L-SpO CLINICAL TRIAL REGISTRATION: ChiCTR2400084998.
3. Predicting Days at Home after Elective Surgery for Gastrointestinal Cancer using HOMEDAYS: Prediction Model Development and Internal Validation.
Using 91,270 cases, the HOMEDAYS model predicts DAH-90 for elective gastrointestinal cancer surgery with strong accuracy (MAE 8.67), excellent calibration (slope 1.0; intercept 0.29), and robust internal validation. Incorporating 23 predictors and 3 interactions, it facilitates individualized, patient-centered risk communication.
Impact: Introduces a rigorously validated, patient-centered prediction tool that synthesizes survival and healthcare utilization into a single, interpretable outcome, enabling better perioperative counseling and planning.
Clinical Implications: Use HOMEDAYS to set realistic expectations for DAH-90 during shared decision-making, tailor perioperative support, and inform discharge planning; external validation and EHR integration will enable broader adoption.
Key Findings
- Large population-based cohort (n=91,270) with median DAH-90 of 82 days (IQR 77-85).
- Model with 23 predictors and 3 interactions achieved MAE 8.67, calibration slope 1.0 (intercept 0.29), g-index 3.27.
- Internal validation via 500-bootstrap resampling showed stable performance; calibration deviation across deciles 0.1-0.6 days.
Methodological Strengths
- Very large, population-based dataset with comprehensive internal validation (500-bootstrap).
- Robust modeling approach (quantile regression, restricted cubic splines) with prespecified sensitivity analyses and strong calibration.
Limitations
- Internal validation only; lacks external validation across other health systems.
- Administrative data may omit clinical nuances; residual confounding and coding variability possible.
Future Directions: Pursue external validation in diverse systems, integrate into EHRs for real-time counseling, and evaluate impact on patient satisfaction, resource use, and postoperative recovery pathways.
BACKGROUND: Patient-centered outcomes after gastrointestinal cancer surgery are poorly captured by traditional metrics, limiting effective preoperative counseling. Days at home within 90 days after surgery (DAH-90) integrates survival and healthcare utilization but lacks a clinically applicable prediction tool. STUDY DESIGN: Adults undergoing elective gastrointestinal cancer resection in Ontario, Canada (2003-2021) were identified using population-based administrative data. A multivariable prediction model (HOMEDAYS) was developed using quantile regression to estimate median DAH-90 based on preoperative patient, cancer, and treatment factors. Model performance was assessed using mean absolute error (MAE), calibration (slope, intercept, decile plots), and discrimination (g-index), with internal validation via 500-bootstrap resampling and prespecified sensitivity analyses. RESULTS: Among 91,270 patients, median DAH-90 was 82 days (IQR 77-85). The final model incorporated 23 predictors with 3 interaction terms and modeled age using restricted cubic splines. Performance demonstrated strong accuracy (MAE 8.67), good calibration (slope 1.0, intercept 0.29), and discrimination (g-index 3.27). Optimism-corrected metrics remained stable (MAE 8.68; slope 1.0; intercept 0.29; g-index 3.26). Calibration across deciles showed minimal deviation between predicted and observed DAH-90 (0.1-0.6 days). Model performance was robust across multiple sensitivity analyses, including alternative outcome definitions and additional predictors. CONCLUSIONS: HOMEDAYS provides accurate, internally validated predictions of DAH-90 using preoperative variables, enabling individualized, patient-centered risk communication for elective gastrointestinal cancer surgery. This tool may enhance shared decision-making and perioperative preparedness.